Erschienen in:
01.08.2005 | Commentary
The benefits and threats of research partnerships with industry
verfasst von:
Gordon DuVal
Erschienen in:
Critical Care
|
Ausgabe 4/2005
Einloggen, um Zugang zu erhalten
Excerpt
During the past two decades, the involvement of non-academic sponsors of biomedical research, particularly clinical trial research, has increased exponentially. It is estimated that between 1980 and 2003 the overall research and development expenditure by US pharmaceutical companies increased from $2 billion to $33 billion [
1]. The sources of funding for biomedical research have also shifted significantly towards industry. By 2002, 70% of funding for clinical trials came from industry [
2]. The involvement of industry partners in research has undoubted benefits. Drug development is extraordinarily expensive, and government and other non-commercial sources of research funding have generally not been able to or willing to underwrite the enormous sums necessary to develop and test the medications and devices that have made remarkable improvements in the lives of so many. …